Aclaris Therapeutics Inc. (ACRS) Trading Up 2.4%
Aclaris Therapeutics Inc. (NASDAQ:ACRS)’s share price was up 2.4% on Friday . The stock traded as high as $20.99 and last traded at $20.71, with a volume of 68,783 shares trading hands. The stock had previously closed at $20.23.
Several equities analysts have recently weighed in on ACRS shares. Zacks Investment Research lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 24th. Guggenheim started coverage on shares of Aclaris Therapeutics in a report on Friday, June 10th. They set a “buy” rating and a $35.00 target price for the company. Finally, Jefferies Group lifted their target price on shares of Aclaris Therapeutics from $20.00 to $23.00 and gave the company a “buy” rating in a report on Friday, August 12th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $29.25.
The company’s market cap is $457.00 million. The stock’s 50 day moving average price is $19.96 and its 200-day moving average price is $19.14.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.01. Equities analysts expect that Aclaris Therapeutics Inc. will post ($2.61) earnings per share for the current fiscal year.
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.